FDA Approved: INQOVI — Supplemental Application (Taiho Pharmaceutical Co., Ltd.)

View source ↗

Summary

The FDA approved a supplemental application for INQOVI, the oral fixed-dose combination of cedazuridine and decitabine from Taiho Pharmaceutical Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Inqovi (decitabine/cedazuridine)

Snippet

SUPPL AP for INQOVI (CEDAZURIDINE AND DECITABINE)